Benefits
GLP-1 Increase (~13%)
Clinical study showed 7 days of supplementation with 100 mg Capsimax increased GLP-1 levels by approximately 13% — relevant to satiety and metabolic health (GLP-1 is satiety hormone, target of GLP-1 receptor agonist drugs).
Energy Expenditure Increase (+120 kcal/day)
Same study showed Capsimax raised resting energy expenditure by more than 120 kcal/day — supports caloric balance for weight management.
Thermogenesis Without Pungency
OmniBead encapsulation allows capsaicinoid systemic delivery without mouth/throat burning.
Weight Management Adjunct
Multiple Capsimax trials show weight management benefits when combined with caloric awareness.
Appetite Control
Capsaicinoid-mediated effects on appetite and food intake.
OmniBead® Controlled Release
Distinguishes from standard capsaicin supplementation by avoiding GI burning while delivering systemic effects.
Mechanism of action
TRPV1 Receptor Activation
Capsaicinoids activate TRPV1 receptors — promotes thermogenesis, brown adipose activation, energy expenditure.
GLP-1 Pathway Activation
Capsaicinoid TRPV1 activation in GI tract triggers GLP-1 release — same hormone targeted by Ozempic/Wegovy/Mounjaro pharmaceuticals; natural support for satiety pathway.
OmniBead Controlled Release
Beadlet technology releases capsaicinoids progressively in intestines avoiding upper GI TRPV1 activation that causes burning.
Brown Adipose Thermogenic Activation
Activates UCP1 thermogenesis in brown and beige adipose tissue.
Catecholamine Release
Modest sympathetic activation supporting energy expenditure.
Clinical trials
Clinical study of 100 mg Capsimax for 7 days on GLP-1 and resting energy expenditure.
Adults.
GLP-1 increased ~13%; resting energy expenditure raised >120 kcal/day. Established Capsimax GLP-1 evidence.
Multiple Capsimax weight management trials.
Adults with weight management concerns.
Body composition improvements; established weight management evidence.
About this ingredient
CAPSIMAX® is a PATENTED CAPSICUM (CAPSAICINOID) EXTRACT developed by OMNIACTIVE — distinguished by OMNIBEAD® encapsulation technology providing CONTROLLED RELEASE without oral pungency. CAPSAICINOID BACKGROUND: pungent compounds in chili peppers; activate TRPV1 receptors; cause burning sensation but also documented metabolic effects.
KEY DISTINCTIONS: (1) PATENTED OmniBead encapsulation; (2) PUNGENCY-FREE delivery; (3) CONTROLLED RELEASE; (4) CLINICAL EVIDENCE for GLP-1 and energy expenditure; (5) OmniActive's flagship metabolic ingredient.
EVIDENCE-BASED USES: (1) GLP-1 INCREASE (~13% in 7 days at 100 mg); (2) Energy expenditure (+120 kcal/day); (3) Weight management; (4) Thermogenesis; (5) Appetite control; (6) Metabolic health support.
CRITICAL CAUTIONS: (1) PREGNANCY — limited safety data; AVOID concentrated supplementation; (2) GERD/GI CONDITIONS — caution; (3) GLP-1 AGONIST DRUGS (Ozempic, Wegovy, Mounjaro) — theoretical additive GLP-1 effects; consult prescriber; (4) ANTICOAGULANTS — modest effects; (5) DOSE — 100 mg/day Capsimax research-validated; (6) DURATION — metabolic effects build with continued use; (7) CAPSIMAX vs CAPSIFEN (Akay) vs GENERIC CAPSAICIN — different bioavailability/delivery technologies; both OmniBead and FenuMat address pungency; both have evidence; (8) GLP-1 NATURAL SUPPORT context — relevant to those interested in GLP-1 pathway without pharmaceutical agonists; modest effect vs medications; (9) WEIGHT MANAGEMENT FRAMEWORK — caloric deficit, exercise foundational; supplements adjunct; thermogenic ingredients modest contribution; (10) BRAND VERIFICATION — Capsimax® and OmniBead® are OmniActive trademarks; specific patented technology; clinical evidence on this branded form.